超细颗粒三联疗法用于有症状且有一次中度急性加重史的慢阻肺患者
在有症状的慢阻肺、重度/极重度气流受限且既往仅一次中度(无重度)急性加重史的患者中,含ICS的三联疗法相比单药或双药维持治疗总体显著降低急性加重风险。急性加重史是预测未来急性加重风险的最强因子,既往一年一次急性加重者风险约为无急性加重者的两倍。
要点
- 有症状慢阻肺且既往仅一次中度急性加重者,含ICS三联疗法可显著降低急性加重风险。
- 急性加重史是未来急性加重最强预测因子,一次急性加重即约两倍风险。
- 多数预防急性加重的药物试验以既往一年至少一次急性加重为入选标准。
核心结论
- 在有症状的慢阻肺、重度/极重度气流受限且既往仅一次中度(无重度)急性加重史的患者中,含ICS的三联疗法相比单药或双药维持治疗总体显著降低急性加重风险。
主要发现
- 既往一年一次急性加重者未来急性加重风险约为无急性加重者的两倍,两次及以上者风险增至五倍。
- 多数预防急性加重的药物临床试验采用既往一年至少一次急性加重为入选标准,少数要求至少两次。
临床怎么用
- 对有症状、重度/极重度气流受限且既往仅一次中度急性加重史的慢阻肺患者,可考虑含ICS的三联疗法以降低急性加重风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with symptomatic COPD, severe/very severe airflow limitation, and a history of one moderate (and no severe) exacerbation, ICS-containing triple therapy significantly reduces exacerbation risk overall versus single or double maintenance therapy http://ow.ly/VgJC30o9pXC In chronic obstructive pulmonary disease (COPD), exacerbation history is the strongest predictor of future exacerbation risk [1, 2]. Large cohort studies have shown that patients with one exacerbation in the previous year have an approximately two-fold increased future exacerbation risk compared to patients with no exacerbations, the risk increasing to five-fold in those with two or more exacerbations [1, 2]. Most clinical trials of pharmacological treatments designed to prevent exacerbations have therefore used the inclusion criterion of at least one exacerbation in the previous year, with a minority requiring at least two exacerbations [3–6].
引用
- Singh D, Fabbri LM, Corradi M, et al. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur Respir J. 2019. PMID: 30792343. doi:10.1183/13993003.00235-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。